A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations

PCN40 Cost-Utility Analysis of Pembrolizumab Versus Platinum Based Chemotherapy As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer (NSCLC) in UK

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.090 ◽

2020 ◽

Vol 22 ◽

pp. S12

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

PCN53 Cost-Utility Analysis of Dacomitinib As First-LINE Treatment for Patients with Locally Advanced or Metastatic NON-SMALL CELL LUNG Cancer in China

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.103 ◽

2020 ◽

Vol 22 ◽

pp. S15

Author(s):

G. Jin ◽

J. Zhao ◽

L. Yang

Keyword(s):

Lung Cancer ◽

Locally Advanced ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Cost-Utility Analysis of Erlotib Versus Standard Chemotherapy in First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam

Value in Health ◽

10.1016/j.jval.2016.03.1614 ◽

2016 ◽

Vol 19 (3) ◽

pp. A154

Author(s):

TT Tran ◽

T Nguyen

Keyword(s):

Egfr Mutation ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Standard Chemotherapy ◽

PRS15 A Cost-Utility Analysis of Dacomitinib As First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 21 L858R Substitution Mutation in China

Value in Health ◽

10.1016/j.jval.2021.04.1079 ◽

2021 ◽

Vol 24 ◽

pp. S215

Author(s):

G. Jin ◽

J. Zhao ◽

L. Luan ◽

P. Dong ◽

L. Yang

Keyword(s):

Locally Advanced ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Substitution Mutation ◽

Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.04.005 ◽

2020 ◽

Vol 21 ◽

pp. 9-16 ◽

Cited By ~ 1

Author(s):

Unchalee Permsuwan ◽

Sumitra Thongprasert ◽

Buntitabhon Sirichanchuen

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous Non-Small-Cell Lung Cancer in Thailand

Value in Health ◽

10.1016/j.jval.2014.08.118 ◽

2014 ◽

Vol 17 (7) ◽

pp. A737

Author(s):

P Tongpak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANON

Value in Health ◽

10.1016/j.jval.2018.09.279 ◽

2018 ◽

Vol 21 ◽

pp. S47

Author(s):

A. Tfayli ◽

F. Elias ◽

F. Farhat ◽

R. Slim ◽

Z. Hallal ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis

Annals of Oncology ◽

10.1093/annonc/mdq431 ◽

2011 ◽

Vol 22 (3) ◽

pp. 567-574 ◽

Cited By ~ 12

Author(s):

M. Joerger ◽

K. Matter-Walstra ◽

M. Früh ◽

U. Kühnel ◽

T. Szucs ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Line Chemotherapy

Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

Value in Health ◽

10.1016/j.jval.2016.09.2253 ◽

2016 ◽

Vol 19 (7) ◽

pp. A740-A741

Author(s):

MS Holleman ◽

R Zaim ◽

CA Uyl-De Groot

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Egfr Mutations ◽

Utility Analysis ◽

Small Cell Lung ◽

PCN43 THE ASSOCIATION OF TUMOR HISTOLOGY WITH FIRST-LINE TREATMENT AND LIFETIME MEDICAL-CARE COSTS AMONG ELDERLY STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH COMMONLY USED DOUBLET THERAPIES AMONG

Value in Health ◽

10.1016/s1098-3015(10)70221-7 ◽

2008 ◽

Vol 11 (3) ◽

pp. A67

Author(s):

K Lang ◽

M Marciniak ◽

D Faries ◽

KM Clements ◽

J Nyambose ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Medical Care Costs ◽

Nsclc Patients ◽

Care Costs ◽